Researchers in Philippines develop machine to quickly detect drug-resistant TB

In this post in the Global Post's "Global Pulse" blog, journalist John Donnelly reports on how a machine developed by researchers at the TB Laboratory at the Lung Center of the Philippines "that can detect multi-drug resistant [tuberculosis (MDR-TB)] in record time may revolutionize TB treatment." According to the blog, the GeneXpert, dubbed by researchers as the "espresso maker," grew out of collaboration among partners put together by the Foundation for Innovative New Diagnostics in Geneva and "can detect [MDR-TB] in two hours instead of the old way of growing cultures that took two months."

"With financial help from the Global Fund to Fight AIDS, TB, and Malaria, the Philippines has purchased 20 GeneXpert machines and has begun to distribute them to provinces around the country," the blog states. Donnelly and photographer Riccardo Venturi visited the lab as the first stop in a three-country tour, during which the pair, acting independently, "met with scientists, doctors and patients to explore the scope of the struggle to fight MDR-TB," Donnelly writes (11/13).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New toolkit aims to help U.S. hospitals spot deadly viral hemorrhagic fevers faster and safer